An Open Label, Phase 2 Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Medical College of Wisconsin
- Enrollment
- 131
- Locations
- 2
- Primary Endpoint
- Overall Mortality
Study Overview
Brief Summary
This is a Phase II study. This research study is being conducted to use convalescent donor plasma in seriously ill patients who have COVID-19.
Detailed Description
This is an open label phase 2 trial assessing the efficacy and safety of anti-SARS-CoV-2 convalescent plasma in hospitalized patients with acute severe respiratory symptoms from COVID-19. Symptomatic patients with clinical or radiological interstitial COVID-19 pneumonia and within 21 days of onset of symptoms will be enrolled in 2 cohorts - an ICU cohort and a hospitalized non-ICU cohort.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age ≥ 18 years or older
- •Hospitalized as an in-patient with positive COVID-19 test by PCR
- •Presence of respiratory symptoms with any of severe features as below:
- •Respiratory Rate ≥ 24/min
- •Oxygen Support >3L/min by nasal cannula
- •New onset or worsening of respiratory symptoms with radiologic confirmation of bilateral ground glass opacities that cannot be attributed to another cause
- •Patient / HCPOA must agree to storage of blood specimens for future testing.
- •Patient / HCPOA is willing and able to provide electronic informed consent and comply with all protocol requirements. If patient is unable to consent due to incapacity, health care POA should be defined and able to consent for the patient.
- •Patients are allowed to receive all standard of care. Co enrollment in other clinical trials is permitted.
Exclusion Criteria
- •FCBP with positive pregnancy test (mandatory)
- •Breastfeeding females
- •Receipt of pooled immunoglobulin (e.g. IVIG or other hyperimmune globulin products) in past 14 days. This does not apply to monoclonal antibodies .
- •Mechanical ventilation for > 14 days
- •Days from symptom onset >21 days
- •Expected survival < 72 hours
- •Contraindication to transfusion or history of prior reactions to transfusion blood products including any proven history of TRALI
- •Patients who were previously admitted to ICU cannot be enrolled in the non-ICU cohort. These patients could need ICU level care subsequently and at that time point could be considered for ICU cohort .
Outcomes
Primary Outcomes
Overall Mortality
Time Frame: Duration of patient hospitalization, sometimes exceeding 60 days
Overall mortality during hospitalization for COVID-19. All patients were followed for the duration of their hospitalization, sometimes exceeding 60 days, through study completion.
Secondary Outcomes
- Length of Admission After Plasma Infusion(Length of admission for COVID through study follow-up period)
- Length of ICU Stay After Convalescent Plasma Infusion(Length of admission in the ICU for COVID through study follow-up period)
Investigators
Mary Beth Graham, MD
Associate Chief, Professor Infectious Disease
Medical College of Wisconsin